NEW YORK (GenomeWeb) – The Alliance Global Group today announced an exclusive master agreement for the distribution of Invivoscribe Technologies' molecular diagnostics in Alliance's markets.

Based in San Diego, Invivoscribe's products include assays for detecting clonal gene rearrangements, gene translocations, and gene mutations in patients with suspected lymphoproliferations, among other things. It also has CLIA- and CAP-certified clinical reference laboratories in the European Union and the US to perform FLT2 and NPM1 mutation testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.